JPRN-UMIN000052618招募中Unknown
Study on PK/PD of immune checkpoint inhibitors according to differential dosage in elderly non-small cell lung cancer patients - Study on PK and PD of pembrolizumab
ational Cancer Center Hospital, Japan0 个研究点目标入组 64 人开始时间: 2023年10月26日最近更新:
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 发起方
- 入组人数
- 64
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients who cannot give consent for specimen collection. 2) Patients who are judged by the principal investigator or the physician in charge to be inappropriate as subjects for this study.
研究者
相似试验
已完成
不适用
PK/PD study of Pembrolizumabon-small cell lung cancerJPRN-UMIN000036606ational Cancer Center Research Institute Division of Molecular Pharmacology100
已完成
不适用
Efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer other than adenocarcinoma or squamous cell carcinoma: multicenter retrospective observational studyon-small cell lung cancer other than adenocarcinoma or squamous cell carcinomaJPRN-UMIN000037777Hamamatsu University School of Medicine60
招募中
不适用
Predictive biomarker study of immune checkpoint inhibitors in metastatic head and neck squamous cell carcinomaNeoplasmsKCT0007598ational Cancer Center50
Unknown
不适用
PD-1 Antibody and Radiotherapy for Recurrent Cervical CancerImmune Checkpoint InhibitorsAnti-programmed Death-1 AntibodyRadiotherapyRecurrent Cervical CarcinomaMetastatic Cervical CarcinomaPersistent Advanced Cervical CarcinomaObjective Remission RateProgression-free SurvivalOverall SurvivalSevere Adverse EventsNCT05310305Lei Li20
已完成
不适用
The usefulness of immune checkpoint inhibitors among lung cancer patients with driver gene mutantsung cancerJPRN-UMIN000040789Yokohama City University